{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Stefanik M"],"funding":["Ministerstvo Zdravotnictví Ceské Republiky","Ministerstvo Školství, Mládeže a Tělovýchovy"],"pagination":["E599"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC7232190"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["8(4)"],"pubmed_abstract":["Vector-borne flaviviruses (VBFs) affect human health worldwide, but no approved drugs are available specifically to treat VBF-associated infections. Here, we performed in silico screening of a library of U.S. Food and Drug Administration-approved antiviral drugs for their interaction with Zika virus proteins. Twelve hit drugs were identified by the docking experiments and tested in cell-based antiviral assay systems. Efavirenz, tipranavir, and dasabuvir at micromolar concentrations were identified to inhibit all VBFs tested; i.e., two representatives of mosquito-borne flaviviruses (Zika and West Nile viruses) and one representative of flaviviruses transmitted by ticks (tick-borne encephalitis virus). The results warrant further research into these drugs, either individually or in combination, as possible pan-flavivirus inhibitors."],"journal":["Microorganisms"],"pubmed_title":["FDA-Approved Drugs Efavirenz, Tipranavir, and Dasabuvir Inhibit Replication of Multiple Flaviviruses in Vero Cells."],"pmcid":["PMC7232190"],"funding_grant_id":["CZ.02.1.01/0.0/0.0/15_003/0000495","16-34238A"],"pubmed_authors":["Salat J","Uzochukwu IC","Ezebuo FC","Fojtikova M","Stefanik M","Valdes JJ","Haviernik J","Eyer L","Ruzek D"],"additional_accession":[]},"is_claimable":false,"name":"FDA-Approved Drugs Efavirenz, Tipranavir, and Dasabuvir Inhibit Replication of Multiple Flaviviruses in Vero Cells.","description":"Vector-borne flaviviruses (VBFs) affect human health worldwide, but no approved drugs are available specifically to treat VBF-associated infections. Here, we performed in silico screening of a library of U.S. Food and Drug Administration-approved antiviral drugs for their interaction with Zika virus proteins. Twelve hit drugs were identified by the docking experiments and tested in cell-based antiviral assay systems. Efavirenz, tipranavir, and dasabuvir at micromolar concentrations were identified to inhibit all VBFs tested; i.e., two representatives of mosquito-borne flaviviruses (Zika and West Nile viruses) and one representative of flaviviruses transmitted by ticks (tick-borne encephalitis virus). The results warrant further research into these drugs, either individually or in combination, as possible pan-flavivirus inhibitors.","dates":{"release":"2020-01-01T00:00:00Z","publication":"2020 Apr","modification":"2024-12-04T09:48:24.101Z","creation":"2020-05-26T07:11:17Z"},"accession":"S-EPMC7232190","cross_references":{"pubmed":["32326119"],"doi":["10.3390/microorganisms8040599"]}}